[go: up one dir, main page]

AR040778A1 - Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). - Google Patents

Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).

Info

Publication number
AR040778A1
AR040778A1 AR20030102790A ARP030102790A AR040778A1 AR 040778 A1 AR040778 A1 AR 040778A1 AR 20030102790 A AR20030102790 A AR 20030102790A AR P030102790 A ARP030102790 A AR P030102790A AR 040778 A1 AR040778 A1 AR 040778A1
Authority
AR
Argentina
Prior art keywords
mag
glicoprotein
honey
functional fragments
altered antibodies
Prior art date
Application number
AR20030102790A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218234A external-priority patent/GB0218234D0/en
Priority claimed from GB0218230A external-priority patent/GB0218230D0/en
Priority claimed from GB0218229A external-priority patent/GB0218229D0/en
Priority claimed from GB0218232A external-priority patent/GB0218232D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR040778A1 publication Critical patent/AR040778A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a anticuerpos alterados a glicoproteína asociada a la mielina (MAG), formulaciones farmacéuticas que los contienen y al uso de dichos anticuerpos en el tratamiento y/o profilaxis de enfermedades/trastornos neurológicos. Reivindicación 1: Un anticuerpo alterado o fragmento funcional del mismo que se une a y neutraliza MAG y que comprende uno o más de las siguientes CDR. Las CDR de cadena ligera según cuadro (1), las CDR de cadena pesada según cuadro (2).
AR20030102790A 2002-08-06 2003-08-04 Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). AR040778A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0218234A GB0218234D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218230A GB0218230D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218229A GB0218229D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218232A GB0218232D0 (en) 2002-08-06 2002-08-06 Antibodies

Publications (1)

Publication Number Publication Date
AR040778A1 true AR040778A1 (es) 2005-04-20

Family

ID=31721633

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102790A AR040778A1 (es) 2002-08-06 2003-08-04 Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).

Country Status (23)

Country Link
US (2) US7612183B2 (es)
EP (1) EP1526868B1 (es)
JP (1) JP4528121B2 (es)
KR (1) KR101078459B1 (es)
CN (1) CN100542607C (es)
AR (1) AR040778A1 (es)
AU (1) AU2003255390B2 (es)
BR (1) BR0312456A (es)
CA (1) CA2494008C (es)
CY (1) CY1114919T1 (es)
DK (1) DK1526868T3 (es)
ES (1) ES2440652T3 (es)
IL (1) IL165478A (es)
IS (1) IS7576A (es)
MX (1) MXPA05001468A (es)
MY (1) MY148409A (es)
NO (1) NO333876B1 (es)
NZ (1) NZ537123A (es)
PL (1) PL211014B1 (es)
PT (1) PT1526868E (es)
SI (1) SI1526868T1 (es)
TW (1) TWI323265B (es)
WO (1) WO2004014953A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986370B2 (ja) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｒｇｍおよびそのモジュレーターの用途
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
MX337061B (es) 2005-11-04 2016-02-11 Genentech Inc Uso de inhibidores de la via del complemento para tratar enfermedades oculares.
WO2007139359A1 (en) * 2006-05-31 2007-12-06 Hanwha Chemical Corporation Vcam-1 specific monoclonal antibody
MY157948A (en) 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
WO2009051957A2 (en) * 2007-10-16 2009-04-23 Nuvelo, Inc. Antibodies to irem-1
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
UY31810A (es) 2008-05-06 2009-12-14 Glaxo Group Ltd Encapsulación de agentes biológicamente activos
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
RU2011135768A (ru) * 2009-01-29 2013-03-10 Эбботт Лэборетриз Белки, связывающие il-1
ES2562832T3 (es) 2009-12-08 2016-03-08 Abbvie Deutschland Gmbh & Co Kg Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
WO2011085289A1 (en) * 2010-01-11 2011-07-14 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Production of a monoclonal antibody therapeutic against west nile virus in plants
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
WO2011159704A1 (en) * 2010-06-14 2011-12-22 Vaccinex, Inc. Anti-vegf antibodies and uses thereof
US8974782B2 (en) * 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
MY194587A (en) 2012-01-27 2022-12-05 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
KR20160098277A (ko) 2013-12-20 2016-08-18 에프. 호프만-라 로슈 아게 개선된 재조합 폴리펩티드 제조 방법
HUE054034T2 (hu) 2014-03-13 2021-08-30 Univ Basel Mielin asszociált glikoprotein elleni IgM antitestekhez kapcsódó szénhidrát ligandumok
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
DK3313879T3 (da) 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrinreceptor-antistoffer med tilpasset affinitet
EP3350193B1 (en) 2015-09-16 2020-12-23 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
WO2017058859A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
CN109952317A (zh) 2016-09-19 2019-06-28 细胞基因公司 使用pd-1结合蛋白治疗免疫病症的方法
CN109481673A (zh) * 2017-09-12 2019-03-19 中国科学院苏州纳米技术与纳米仿生研究所 促进脑损伤神经修复的组合物及其应用与评价方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK84787D0 (da) 1987-02-19 1987-02-19 Axel Olsen Listesystem til foering af elektriske stroemforsynings- og/eller svagstroemsledere
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5154927A (en) * 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
FI93513C (fi) 1993-11-04 1995-04-25 Matti Kangasvuori Ketju sekä menetelmä ketjun tekemiseksi
EP0804237B8 (en) * 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
CA2218599A1 (en) 1995-04-19 1996-10-24 Acorda Therapeutics Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same
US5932542A (en) * 1995-06-27 1999-08-03 Research Foundation Of Cuny, Hunter College Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
AU724856B2 (en) * 1995-06-30 2000-10-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US5962434A (en) 1995-08-25 1999-10-05 The Johns Hopkins University School Of Medicine Compounds for stimulating nerve growth
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CA2266341A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
WO1999021581A1 (en) * 1997-10-28 1999-05-06 Steeves John D Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
CN1294517A (zh) 1997-11-14 2001-05-09 欧洲细胞技术有限公司 具有合成可变区和修饰特异性的免疫球蛋白分子
AU3134799A (en) 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DK1098972T3 (da) 1998-07-22 2011-01-03 Smithkline Beecham Ltd Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
CA2343313A1 (en) * 1998-09-14 2000-03-23 Lars Ostergaard Pedersen A method of producing a functional immunoglobulin superfamily protein
BR9915137A (pt) 1998-11-06 2004-06-08 Martin E Schwab Proteìna, fragmento purificado de uma proteìna, molécula purificada, ácido nucleico, vetor, célula recombinante, métodos de produção de uma proteìna recombinante, de tratamento de um indivìduo com uma doença neoplásica do sistema nervoso central e com dano no sistema nervoso central, de induzir regeneração ou brotação de neurÈnios em um indivìduo, de promoção de plasticidade estrutural do sistema nervoso central de um indivìduo, e, animal não-humano recombinante, método de obtenção de anticorpos policlonais para uma proteìna, amostra de anti-soro isolada, e, método de imunização de um animal não-humano
AU775525B2 (en) 1999-01-22 2004-08-05 Auckland Technology Enabling Corporation Limited Vaccine-mediated treatment of neurological disorders
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
WO2001062907A1 (fr) * 2000-02-22 2001-08-30 Medical & Biological Laboratories Co., Ltd. Bibliotheque d'anticorps
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Also Published As

Publication number Publication date
CA2494008A1 (en) 2004-02-19
CN1671417A (zh) 2005-09-21
JP4528121B2 (ja) 2010-08-18
HK1077206A1 (en) 2006-02-10
US20090053214A1 (en) 2009-02-26
US20060165681A1 (en) 2006-07-27
NO333876B1 (no) 2013-10-07
WO2004014953A2 (en) 2004-02-19
IS7576A (is) 2004-11-30
AU2003255390B2 (en) 2011-02-03
BR0312456A (pt) 2005-04-19
TW200403254A (en) 2004-03-01
ES2440652T3 (es) 2014-01-29
NZ537123A (en) 2007-05-31
SI1526868T1 (sl) 2014-01-31
NO20045323L (no) 2005-02-10
IL165478A (en) 2010-12-30
CA2494008C (en) 2012-12-11
PT1526868E (pt) 2014-01-07
EP1526868B1 (en) 2013-10-23
CN100542607C (zh) 2009-09-23
EP1526868A2 (en) 2005-05-04
AU2003255390A1 (en) 2004-02-25
WO2004014953A3 (en) 2004-05-06
US7612183B2 (en) 2009-11-03
PL375405A1 (en) 2005-11-28
CY1114919T1 (el) 2016-12-14
DK1526868T3 (da) 2014-01-13
TWI323265B (en) 2010-04-11
JP2006512899A (ja) 2006-04-20
KR101078459B1 (ko) 2011-10-31
MY148409A (en) 2013-04-30
MXPA05001468A (es) 2005-06-06
US8071731B2 (en) 2011-12-06
PL211014B1 (pl) 2012-03-30
KR20050049470A (ko) 2005-05-25

Similar Documents

Publication Publication Date Title
AR040778A1 (es) Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
CL2012000518A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de mieloma en un mamífero (div. sol. 3615-07).
CY1111812T1 (el) Ανθρωπινα εξουδετερωτικα αντι-ifn-γ αντισωματα ως εκλεκτικοι αναστολεις του μονοπατιου της ifn-γ
CL2021000293A1 (es) Anticuerpos anti-trem2 y métodos relacionados (divisional de solicitud no.202001575)
PL411824A1 (pl) Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22
CL2020002873A1 (es) Anticuerpos anti-msr1 y métodos de uso de los mismos.
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
LU93067I2 (fr) Blinatumomab et ses dérivés pharmaceutiquement acceptables (blincyto)
CY1113610T1 (el) Συνθεσεις και μεθοδοι για αγωγη μιτοχονδριακων παθησεων
CL2009000234A1 (es) Compuestos derivados de hetero-pentaciclo-fenilo fusionados; composicion farmaceutica; y uso en el tratamiento de la inflamacion, enfermedad autoinmune, trastornos oseos destructivos, transtorno proliferativo, infecciones bacterianas y virales, enfermedad neurodegenerativa. (divisional de solicitud n° 2004-0416).
UY29284A1 (es) Anticuerpos ab(beta) humanizados usados en mejorar la cognicion
PE20110797A1 (es) Anticuerpos anti mn
ECSP045098A (es) Procedimientos para tratar enfermedades neovasculares oculares
PL377091A1 (pl) Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
DK1401458T3 (da) Sammensætning bestående af PHY906 og kemoterapeutiske midler
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
PE20091327A1 (es) Composicion farmaceutica que comprende anticuerpos monoclonales
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
CR9393A (es) Anticuerpos anti-ccr5 y usos de los mismos
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
CY1108799T1 (el) Αντισωμα αντι- ccr5

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee